ETF PROAI

IDEVvsXPH

iShares Core MSCI International Developed Markets ETF against SPDR S&P Pharmaceuticals ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
IDEV 111XPH 132Oct 25Oct 26GROWTH OF $100
Head to head
IDEVXPH
Expense ratio0.040%0.35%
Assets$32.2B$524M
Net flow, 1 month+$892M−$43M
Net flow, 1 year+$7.3B+$271M
Return, YTD+8.6%+13.6%
Return, 1 year+10.9%+31.8%
Avg daily volume1.9M188K
Holdings228141
ListedMar 21, 2017Jun 19, 2006
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

THE DESK BRIEF

Flows, fee cuts, and closure risk on the funds you watch — every trading morning.